Literature DB >> 20634484

Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation.

Ronen Beeri1, Miguel Chaput, J Luis Guerrero, Yoshiaki Kawase, Chaim Yosefy, Suzan Abedat, Ioannis Karakikes, Charlotte Morel, Ashley Tisosky, Suzanne Sullivan, Mark D Handschumacher, Dan Gilon, Gus J Vlahakes, Roger J Hajjar, Robert A Levine.   

Abstract

BACKGROUND: Mitral regurgitation (MR) doubles mortality after myocardial infarction (MI). We have demonstrated that MR worsens remodeling after MI and that early correction reverses remodeling. Sarcoplasmic reticulum Ca(+2)-ATPase (SERCA2a) is downregulated in this process. We hypothesized that upregulating SERCA2a might inhibit remodeling in a surgical model of apical MI (no intrinsic MR) with independent MR-type flow. METHODS AND
RESULTS: In 12 sheep, percutaneous gene delivery was performed by using a validated protocol to perfuse both the left anterior descending and circumflex coronary arteries with occlusion of venous drainage. We administered adeno-associated virus 6 (AAV6) carrying SERCA2a under a Cytomegalovirus promoter control in 6 sheep and a reporter gene in 6 controls. After 2 weeks, a standardized apical MI was created, and a shunt was implanted between the left ventricle and left atrium, producing regurgitant fractions of ≈30%. Animals were compared at baseline and 1 and 3 months by 3D echocardiography, Millar hemodynamics, and biopsies. The SERCA2a group had a well-maintained preload-recruitable stroke work at 3 months (decrease by 8±10% vs 42±12% with reporter gene controls; P<0.001). Left ventricular dP/dt followed the same pattern (no change vs 55% decrease; P<0.001). Left ventricular end-systolic volume was lower with SERCA2a (82.6±9.6 vs 99.4±9.7 mL; P=0.03); left ventricular end-diastolic volume, reflecting volume overload, was not significantly different (127.8±6.2 vs 134.3±9.4 mL). SERCA2a sheep showed a 15% rise in antiapoptotic pAkt versus a 30% reduction with the reporter gene (P<0.001). Prohypertrophic activated STAT3 was also 41% higher with SERCA2a than in controls (P<0.001). Proapoptotic activated caspase-3 rose >5-fold during 1 month in both SERCA2a and control animals (P=NS) and decreased by 19% at 3 months, remaining elevated in both groups.
CONCLUSIONS: In this controlled model, upregulating SERCA2a induced better function and lesser remodeling, with improved contractility, smaller volume, and activation of prohypertrophic/antiapoptotic pathways. Although caspase-3 remained activated in both groups, SERCA2a sheep had increased molecular antiremodeling "tone." We therefore conclude that upregulating SERCA2a inhibits MR-induced post-MI remodeling in this model and thus may constitute a useful approach to reduce the vicious circle of remodeling in ischemic MR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634484      PMCID: PMC2939951          DOI: 10.1161/CIRCHEARTFAILURE.109.891184

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  50 in total

1.  Kinetics of recombinant adeno-associated virus-mediated gene transfer.

Authors:  A K Malik; P E Monahan; D L Allen; B G Chen; R J Samulski; K Kurachi
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Design of a new surgical approach for ventricular remodeling to relieve ischemic mitral regurgitation: insights from 3-dimensional echocardiography.

Authors:  N Liel-Cohen; J L Guerrero; Y Otsuji; M D Handschumacher; L G Rudski; P R Hunziker; H Tanabe; M Scherrer-Crosbie; S Sullivan; R A Levine
Journal:  Circulation       Date:  2000-06-13       Impact factor: 29.690

3.  Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase.

Authors:  U Schmidt; F del Monte; M I Miyamoto; T Matsui; J K Gwathmey; A Rosenzweig; R J Hajjar
Journal:  Circulation       Date:  2000-02-22       Impact factor: 29.690

4.  Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a.

Authors:  S E Harding; U Schmidt; T Matsui; Z B Kang; G W Dec; J K Gwathmey; A Rosenzweig; R J Hajjar
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

5.  Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats.

Authors:  Y Sakata; T Masuyama; K Yamamoto; N Nishikawa; H Yamamoto; H Kondo; K Ono; K Otsu; T Kuzuya; T Miwa; H Takeda; E Miyamoto; M Hori
Journal:  Circulation       Date:  2000-10-31       Impact factor: 29.690

6.  Mechanism of ischemic mitral regurgitation with segmental left ventricular dysfunction: three-dimensional echocardiographic studies in models of acute and chronic progressive regurgitation.

Authors:  Y Otsuji; M D Handschumacher; N Liel-Cohen; H Tanabe; L Jiang; E Schwammenthal; J L Guerrero; L A Nicholls; G J Vlahakes; R A Levine
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

7.  Contractile reserve and intracellular calcium regulation in mouse myocytes from normal and hypertrophied failing hearts.

Authors:  K Ito; X Yan; M Tajima; Z Su; W H Barry; B H Lorell
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

8.  Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination.

Authors:  S M Young; D M McCarty; N Degtyareva; R J Samulski
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 9.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Authors:  J N Cohn; R Ferrari; N Sharpe
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

10.  New efficient catheter-based system for myocardial gene delivery.

Authors:  Ronen Beeri; J Luis Guerrero; Gregory Supple; Suzanne Sullivan; Robert A Levine; Roger J Hajjar
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

View more
  27 in total

Review 1.  Model-specific selection of molecular targets for heart failure gene therapy.

Authors:  Michael G Katz; Anthony S Fargnoli; Catherine E Tomasulo; Louella A Pritchette; Charles R Bridges
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

Review 2.  Calcium cycling proteins and their association with heart failure.

Authors:  L Hadri; R J Hajjar
Journal:  Clin Pharmacol Ther       Date:  2011-08-10       Impact factor: 6.875

Review 3.  Mitral valve disease--morphology and mechanisms.

Authors:  Robert A Levine; Albert A Hagége; Daniel P Judge; Muralidhar Padala; Jacob P Dal-Bianco; Elena Aikawa; Jonathan Beaudoin; Joyce Bischoff; Nabila Bouatia-Naji; Patrick Bruneval; Jonathan T Butcher; Alain Carpentier; Miguel Chaput; Adrian H Chester; Catherine Clusel; Francesca N Delling; Harry C Dietz; Christian Dina; Ronen Durst; Leticia Fernandez-Friera; Mark D Handschumacher; Morten O Jensen; Xavier P Jeunemaitre; Hervé Le Marec; Thierry Le Tourneau; Roger R Markwald; Jean Mérot; Emmanuel Messas; David P Milan; Tui Neri; Russell A Norris; David Peal; Maelle Perrocheau; Vincent Probst; Michael Pucéat; Nadia Rosenthal; Jorge Solis; Jean-Jacques Schott; Ehud Schwammenthal; Susan A Slaugenhaupt; Jae-Kwan Song; Magdi H Yacoub
Journal:  Nat Rev Cardiol       Date:  2015-10-20       Impact factor: 32.419

Review 4.  Cardiac gene therapy.

Authors:  Antoine H Chaanine; Jill Kalman; Roger J Hajjar
Journal:  Semin Thorac Cardiovasc Surg       Date:  2010

Review 5.  The potential of adeno-associated viral vectors for gene delivery to muscle tissue.

Authors:  Dan Wang; Li Zhong; M Abu Nahid; Guangping Gao
Journal:  Expert Opin Drug Deliv       Date:  2014-01-03       Impact factor: 6.648

6.  Potential of gene therapy as a treatment for heart failure.

Authors:  Roger J Hajjar
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

7.  Anticipating the Vicious Circle of Postinfarction Mitral Regurgitation: Imaging Insights.

Authors:  Jacob P Dal-Bianco; Philipp E Bartko; Robert A Levine
Journal:  Circ Cardiovasc Imaging       Date:  2016-07       Impact factor: 7.792

Review 8.  Gene therapy for heart failure.

Authors:  Lisa Tilemann; Kiyotake Ishikawa; Thomas Weber; Roger J Hajjar
Journal:  Circ Res       Date:  2012-03-02       Impact factor: 17.367

Review 9.  Cardiovascular gene therapy for myocardial infarction.

Authors:  Maria C Scimia; Anna M Gumpert; Walter J Koch
Journal:  Expert Opin Biol Ther       Date:  2013-12-16       Impact factor: 4.388

Review 10.  Use of Adeno-Associated Virus Vector for Cardiac Gene Delivery in Large-Animal Surgical Models of Heart Failure.

Authors:  Michael G Katz; Anthony S Fargnoli; Thomas Weber; Roger J Hajjar; Charles R Bridges
Journal:  Hum Gene Ther Clin Dev       Date:  2017-07-19       Impact factor: 5.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.